TRANSIT: Second TAVR Procedure Maybe Be Safe, Effective in Younger/Low-Risk Patients With Degenerated Bioprosthetic Valves

"The expanding adoption of TAVR to relatively young and/or low-risk patients will conceivably result in an increasing number of patients with a degenerated bioprosthetic valve," said Luca Testa, MD, PhD, presenting results of the TRANSIT study Oct. 17 during TCT 2020. "These patients may be safely and successfully treated by means of a second transcatheter procedure."

The TRANSIT study is based on registry data from more than 172 patients at 28 centers from Europe, North America, South America and the Middle East who underwent a second TAVR due to a degenerated transcatheter aortic bioprosthesis. Patients were analyzed based on the mode of failure of the first bioprosthetic valve (57 stenosis, 97 regurgitation, 18 mixed).

Results showed an overall mortality rate at one year of 10% and a cardiovascular mortality rate of 5.8%. Low rates of major clinical events were also observed, as were significant clinical benefits based on the rate of hospitalizations and NYHA class.

"The impact of this study for patients affected by degenerated aortic bioprosthesis is considerable as they have very limited options and an unfavorable prognosis," said Testa, et al. "In terms of delivery of care, this study provides evidence on a treatment that will be considered for a continuously growing number of patients."

Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and VHD, Interventions and Structural Heart Disease

Keywords: TCT20, Transcatheter Cardiovascular Therapeutics, Percutaneous Coronary Intervention, Aortic Valve Stenosis, Aortic Valve, Transcatheter Aortic Valve Replacement


< Back to Listings

ACC Members, discuss
this on Member Hub.